Vertex Pharmaceuticals
VRTX
1,108 hedge funds and large institutions have $66B invested in Vertex Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 133 funds opening new positions, 361 increasing their positions, 440 reducing their positions, and 78 closing their positions.
71% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 78
33% more funds holding in top 10
Funds holding in top 10: 24 → 32 (+8)
17% more capital inflows, than outflows
Capital inflows: $4.51B | Capital outflows: $3.86B
3% more funds holding
Funds holding: 1,072 → 1,108 (+36)
0.2% less ownership
Funds ownership: 92.2% → 91.99% (-0.2%)
3% less call options, than puts
Call options by funds: $451M | Put options by funds: $463M
18% less repeat investments, than reductions
Existing positions increased: 361 | Existing positions reduced: 440
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$956M |
| 2 |
Jennison Associates
New York
|
+$381M |
| 3 |
BlackRock
New York
|
+$327M |
| 4 |
Morgan Stanley
New York
|
+$268M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$221M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$517M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$336M |
| 3 |
ClearBridge Investments
New York
|
-$243M |
| 4 |
D.E. Shaw & Co
New York
|
-$125M |
| 5 |
Man Group
London,
United Kingdom
|
-$115M |
VRTX Hedge Fund Activity: Q2 2022 in Review
1,108 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2022, worth a combined $66B — up 8.4% from $60.9B a quarter earlier.
Buyers outnumbered sellers: 133 funds opened new VRTX positions and 78 closed out — a net gain of 55 holders — while 361 added to existing stakes and 440 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $956M. The largest seller was Loomis, Sayles & Company, cutting an estimated $517M.
- 1,108 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2022, up from 1,072 in Q1 2022.
- Funds reported $66B of Vertex Pharmaceuticals stock for Q2 2022, up 8.4% quarter-over-quarter.
- 133 funds opened new Vertex Pharmaceuticals positions in Q2 2022 and 78 closed out, a net change of +55 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2022 was Fidelity Investments, an estimated $956M added.
- The largest Vertex Pharmaceuticals seller in Q2 2022 was Loomis, Sayles & Company, an estimated $517M sold.
Based on aggregated 13F filings for Q2 2022.